AEM vs BVN

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

BVN exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating solid operational and financial performance. Despite this, the stock trades at a significant premium to both the Graham Number ($24.27) and intrinsic value estimate ($12.53), raising valuation concerns. While profitability metrics are robust—evidenced by a 30.70% profit margin and 35.35% operating margin—earnings growth is negative year-over-year (-29.50%), creating a divergence between quality and momentum. Analysts concur with a 'hold' recommendation, aligning with the mixed signals between strong fundamentals and stretched valuation.